Moleculin Biotech (NASDAQ:MBRX – Get Free Report) and Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Institutional and Insider Ownership
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 3.4% of Moleculin Biotech shares are held by company insiders. Comparatively, 3.6% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Moleculin Biotech and Dogwood Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moleculin Biotech | N/A | -1,498.41% | -114.47% |
| Dogwood Therapeutics | N/A | N/A | -35.11% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moleculin Biotech | 1 | 0 | 2 | 0 | 2.33 |
| Dogwood Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Moleculin Biotech presently has a consensus target price of $4.00, indicating a potential upside of 720.34%. Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 105.83%. Given Moleculin Biotech’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Dogwood Therapeutics.
Valuation and Earnings
This table compares Moleculin Biotech and Dogwood Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moleculin Biotech | N/A | N/A | -$21.76 million | ($3.27) | -0.15 |
| Dogwood Therapeutics | N/A | N/A | -$12.35 million | ($24.93) | -0.23 |
Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Moleculin Biotech has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.
Summary
Moleculin Biotech beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks.
About Moleculin Biotech
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
About Dogwood Therapeutics
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
